SRA's number for the day: 26
This article was originally published in SRA
European pharmaceutical industry federation EFPIA has issued 26 pages of comment on the European Medicines Agency's draft policy on the disclosure of clinical trial data1,2.
You may also be interested in...
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Viela and Roche both now have marketing applications that are being reviewed by the European Medicines Agency. If approved in the EU, their products will compete with Alexion’s blockbuster Soliris.
Most of the products currently supplied under Australia’s custom-made medical device exemption will no longer be eligible for supply in this way.